Jeff Baxter, VBI Vaccines CEO (ChromaDex)

VBI Vac­cines ex­ecs tout ap­proval of new triple-anti­gen he­pati­tis B shot. Can they sell it?

VBI Vac­cines cel­e­brat­ed a new ap­proval Wednes­day morn­ing, an­nounc­ing the FDA has green­light­ed its he­pati­tis B vac­cine for adults. But ques­tions re­main on how well the new shot will sell.

The biotech in­tends to hit the mar­ket in the first quar­ter of next year, join­ing three oth­er adult he­pati­tis B vac­cines from Mer­ck, Dy­navax and Glax­o­SmithK­line. CEO Jeff Bax­ter said in an an­a­lyst call Wednes­day the price of VBI’s shot, brand­ed as Pre­Hevbrio, won’t be re­vealed un­til com­mer­cial­iza­tion, but claimed it would be “high­ly com­pet­i­tive.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.